Skip to content
lifestyle.presbycamp.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Editas Medicine, Inc.
Editas Medicine Announces Proposed Public Offering
May 26, 2026
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
May 26, 2026
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
May 14, 2026
Editas Medicine Announces First Quarter 2026 Results and Business Updates
May 5, 2026
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
April 27, 2026
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
March 27, 2026
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
March 9, 2026
Editas Medicine to Participate in Upcoming Investor Conferences
February 23, 2026